Less Is More: Destiny Phase IIb Trial Population Reduced
Move Agreed With FDA Will Speed Up XF-73 Trial
Destiny’s Phase IIb clinical study of lead asset XF-73 in the prevention of post-surgical bacterial infections got a boost from trial protocol amendments agreed with the FDA.
You may also be interested in...
Destiny Pharma's XF-73 achieved an "exceptionally high" 99.5% reduction in Staphylococcus aureus bacterial nasal carriage in a mid-stage trial, a result that should attract a number of potential partners for the UK firm.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.